ArticleFrontiers in cardiovascular medicine2026
Evaluation of hepatic infantile hemangiomas: the potential of contrast-enhanced ultrasound.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate laboratory parameters and to compare diagnostic findings of contrast-enhanced ultrasound (CEUS) and magnetic resonance imaging (MRI) in a cohort of patients with hepatic infantile hemangiomas (IH). Materials and Methods: A retrospective multicenter analysis was conducted to identify infants diagnosed with hepatic IH who underwent CEUS, MRI, or both between 2016 and 2024. Lesion size and count were compared in patients who underwent both imaging modalities (6 patients). Data from 24 patients were included in the analysis; in 18 of them, only a single diagnostic imaging examination was performed. Results: Laboratory parameters were mostly unremarkable, only Pro-Brain Natriuretic Peptide (proBNP) was elevated in a subset of patients. Of 24 patients, 15 underwent only CEUS, 3 underwent only MRI, and 6 received both imaging modalities. CEUS findings were comparable to MRI regarding lesion size and number. Treatment decisions were predominantly based on CEUS findings. Conclusion: Although laboratory abnormalities were uncommon, targeted assessment of proBNP and thyroid function may be clinically relevant in infants with extensive hepatic involvement. Both imaging modalities detected hepatic IH. CEUS demonstrated diagnostic findings largely consistent with MRI in hepatic hemangioma evaluation, suggesting its potential as a complementary tool without compromising disease severity assessment. CEUS advantages include real-time imaging and avoidance of sedation or anesthesia in young patients. These findings support the potential role of CEUS as a viable, readily available, and resource-efficient alternative to MRI for the evaluation of hepatic IH, enabling optimization of diagnostic and treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.